TORONTO, Sept. 29, 2021 (GLOBE NEWSWIRE) — PharmaTher Holdings Ltd. (the “Company” or “PharmaTher”) (OTCQB: PHRRF) (CSE: PHRM), a clinical-stage psychedelics biotech company, today announced that Dr. Thomas Laughren has been retained by PharmaTher as a Regulatory Affairs Advisor. Dr. Laughren will advise on regulatory matters as it pertains to KETABET , the Company’s patented combination…


Previous articleRed Light Holland: Initial Results From Red Light Oregon Market Research in Oregon Show 86% of Adults Interested in Psilocybin Services are Interested in Microdosing
Next articlePsyence Group and Pure Extracts Finalize “Pure Psyence,” A Joint Venture for the Development of Psychedelic Medicinal Mushroom Extracts